Smart partnerships that advance cell and gene therapy
Current Kiniciti Operating Companies Include:
Cellistic’s goal is to meet a distinct and increasingly important market need: To develop novel iPSC-based manufacturing technologies that give therapeutic developers access to the scale they need to make their cell therapies a reality. And as they achieve their objectives, so, too, will the patients who depend on access to more affordable, effective cell therapies to treat their severe conditions.
For the past decade at Ncardia, the team has collaborated with a broad array of clients to forge ahead their drug discovery programs for cardiovascular and neurological diseases. Throughout that process, they’ve leveraged human iPSC products and services to increase their probability of downstream success in the discovery and development of new therapies. Ncardia leans into advanced technology to provide the right solutions: high-quality cells, relevant screening assays and robust iPSC differentiation processes for drug discovery and regenerative medicine.
Where Urgency and Capability Meet
Kiniciti invests in opportunities with the potential to leverage technology and capabilities that can drive transformational change and ensure the promise of cell and gene therapies is delivered to patients in need. So we’re ready and able to pursue partnerships in:
Cell sources and other enabling quality-controlled starting and raw materials
Enabling technology platforms (including cell-programming and gene-editing innovations)
Key tools, services and enablers for process development and scale-up
Innovations and solutions from source-to-patient delivery
Other solutions designed to fulfill the promise of breakthrough treatments while concurrently reducing costs to ensure affordable access for patients
Leverage Our Advantages
Speed
A focused, nimble team with an ability to act quickly and decisively to initiate and close partnerships with no layers of bureaucracy
Resources
The backing of a $27BN investment leader with decades of experience building healthcare platforms
Flexibility
A highly tailored approach that provides an adaptable investment philosophy – created uniquely for each partnership
About Our Team
Industry intelligence. Business savvy. Serious capital. This is what Kiniciti brings to the table. Our team comprises some of the most experienced professionals in investing in and building successful companies across the Life Sciences sector.
Contact
We are actively working on growing and developing key partnerships throughout the cell and gene therapy market. Connect with us to explore how our team can support your short- and long-term goals.